Adjuvant High-Dose Intravenous Immunoglobulin Therapy Can Be Easily and Safely Introduced as an Alternative Treatment in Patients with Severe Pemphigus VulgarisA Retrospective Preliminary Study

被引：0

作者：

Michele Davide Mignogna

Stefania Leuci

Stefano Fedele

Elvira Ruoppo

Daniela Adamo

Giuseppina Russo

Raffaella Pagliuca

机构：

[1] University of Naples “Federico II“,Section of Oral Medicine, Department of Odontostomatological and Maxillofacial Sciences

[2] University College London,Oral Medicine Unit, Division of Maxillofacial Diagnostic, Medical and Surgical Sciences, Eastman Dental Institute

[3] Second University of Naples,Section of Immunopathology,Department of General Pathology

[4] University of Naples “Federico II“,Section of Centralized Pharmacology

来源：

American Journal of Clinical Dermatology | 2008年 / 9卷

关键词：

Kawasaki Disease; Mixed Connective Tissue Disease; IVIg Therapy; Mucous Membrane Pemphigoid; Bullous Disease;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Background: Long-term corticosteroid therapy, often in association with other immunosuppressive agents, is considered the mainstay of pemphigus vulgaris (PV) therapy. Recent evidence has been changing this paradigm as patients who are non-responsive to conventional therapies or who experience severe adverse effects have been successfully treated with high-dose intravenous immunoglobulin (IVIg). However, the shift from conventional therapies to IVIg represents a major challenge in the daily practice of non-experienced clinicians because of potential adverse effects and other issues relevant to IVIg therapy such as the necessity for premedication, selection of cases, modality of infusion, patient monitoring, and the cost and length of hospital stay.

引用

页码：323 / 331

页数：8